Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

ONTX was reduced by Zacks.com  from a “acquire” rating to a “hold” score in a research note issued to financiers on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It concentrates on uncovering as well as developing little molecule medicine prospects to deal with cancer cells. The Business‘s items under different stages of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research experts additionally just recently commented on the company. Noble Financial reissued a “buy” score as well as released a $11.00 price purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and also established a “purchase” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day moving ordinary rate of $2.90 and a two-hundred day moving ordinary price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly profits results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) earnings per share for the quarter, topping experts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% and also an unfavorable web margin of 8,294.27%. The firm had income of $0.06 million throughout the quarter, contrasted to the consensus estimate of $0.06 million. During the exact same quarter in the prior year, the firm published ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will post -1.18 EPS for the current year.

A number of hedge funds have actually lately dealt shares of ONTX. GSA Capital Partners LLP purchased a brand-new placement in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Funding Monitoring LP acquired a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a new placement in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP bought a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and various other institutional financiers possess 13.36% of the firm’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the identification as well as advancement of oncology therapeutics. It focuses on finding and developing small molecule medicine prospects to deal with cancer cells. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a free copy of the Zacks research report on Onconova Therapeutics (ONTX).

To learn more regarding research offerings from Zacks Investment Research, browse through Zacks.com.

This instant information alert was generated by narrative science innovation and also economic information from Market in order to give readers with the fastest as well as most accurate reporting. This story was evaluated by Market’s content team prior to publication. 



Prior to you think about Onconova Therapeutics, you’ll intend to hear this.

Market keeps track of Wall Street’s top-rated as well as finest executing research experts and the stocks they suggest to their customers daily. Market has actually recognized the five stocks that top experts are silently whispering to their clients to buy currently prior to the wider market catches on … and Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics presently has a “Buy” rating among experts, top-rated analysts believe these 5 stocks are better purchases.